Endocrine Abstracts

Adrenocortical carcinomas (ACC) are rare and usually very aggressive tumors with heterogeneous outcomes. The individual variability in tumor progression and patients’ survival is linked to ACC biology and molecular heterogeneity, reinforcing the need to identify markers with prognosis value, to allow an accurate clinical strategy. Currently, in the absence of specific molecular markers, ACC prognosis is mainly predicted by the European Network for the Study of Adrenal Tum...

Most of adrenocortical tumors (ACT) are benign and non-functioning tumors, in contrast to adrenocortical carcinomas (ACC), which are rare and usually very aggressive tumors with a poor prognosis. The pathological discrimination between adrenocortical adenomas (ACA) and ACC is mainly based on unspecific and subjective histological features, resulting in inaccurate diagnosis in several cases. Numerous studies have previously described the potential value of immunohistochemistry ...